Remaining Unmet Needs in Biomarker Testing in Early-stage NSCLC

This segment examines optimal care for patients with early-stage non–small cell lung cancer (NSCLC) relying on coordinated multidisciplinary collaboration. Pulmonologists often establish the initial diagnosis and perform staging procedures, while pathologists confirm histology and assess tissue adequacy. Medical oncologists typically oversee next-generation sequencing (NGS) and systemic therapy planning, with surgeons and radiation oncologists determining local treatment options. Early referral to a multidisciplinary tumor board helps align decisions and streamline care. Best practices include integrating tissue-based molecular profiling with liquid biopsy, balancing the comprehensive insight of tissue testing against the speed and minimal invasiveness of blood-based assays. Artificial intelligence is expected to enhance biomarker interpretation, workflow efficiency, and risk stratification. Ongoing unmet needs include standardized testing pathways, broader trial access, and improved options for non-surgical candidates. Clinicians stay current through guidelines, conferences, and trials, with structured surveillance guiding post-surgical monitoring for recurrence.